Mechanisms by which posttransplant maintenance therapy can reduce the risk of disease relapse
| Antitumor activity against residual leukemic stem and progenitor cells |
| Postponement of disease relapse thereby buying time for the genesis of a GVL effect |
| Manipulation of the kinetics of disease relapse permitting postponement of DLI to a later time posttransplant when the risk of severe GVHD is reduced |
| Pharmacologic manipulation of a GVL response using agents such as azacitidine or sorafenib |
| Antitumor activity against residual leukemic stem and progenitor cells |
| Postponement of disease relapse thereby buying time for the genesis of a GVL effect |
| Manipulation of the kinetics of disease relapse permitting postponement of DLI to a later time posttransplant when the risk of severe GVHD is reduced |
| Pharmacologic manipulation of a GVL response using agents such as azacitidine or sorafenib |